Akari Therapeutics ’ Nomacopan Granted U.S. Orphan Drug Designation for Bullous Pemphigoid

NEW YORK and LONDON, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc(Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement (C5) and/or...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials